Danny Luan

Current a first year hemonc fellow at @WCMHemOncFellow. Formerly medical student and internal medicine resident at @WeillCornell. Opinions = my own.

[Danny Luan @DannyLuan6]

Special kudos to Dr. Zhengming Chen who worked tirelessly on developing this cEFS model! Additionally thankful for mentorship from Dr. Peter Martin!

[Danny Luan @DannyLuan6]

Excited to share that our paper on developing a novel conditional event-free survival (cEFS) tool in DLBCL has finally been published!

https://t.co/tdFwAXozeZ

[Danny Luan @DannyLuan6]

A truly multi-institutional collaboration featuring @WCMLymphoma, @MayoClinic, @uiowa, @washumedicine, @umiamimedicine, @UTMDAnderson, @UNC, @UR_Med, @EmoryMedicine, @nyulangone, @AalborgUH among others!

[Roni Shouval @RShouval]

A balanced discussion on the impact of #CART infusion timing in LBCL @BrianHill_MDPhD @AgrimaMianMD https://t.co/h08F7f5mpF

[Waggoner Lab @LabWaggoner]

Impact of time-of-day of infusion of CAR T-cell therapy in patients with relapsed/refractory B-cell lymphoma
pre-noon > post-noon for prolonged progression-free survival (no Δ toxicity)
@BloodPortfolio
https://t.co/MrKQbgelhR
https://t.co/DodkP27WhK @RShouval @KRejeski @MSKCC

[Blood Journals Portfolio @BloodPortfolio]

Earlier infusion time of CAR T-cell therapy was independently associated with improved PFS in large B-cell lymphoma. Read in Blood: https://t.co/yVpzbjMf1H

[Danny Luan @DannyLuan6]

Finally published in print! Time of day of CAR T-cell infusion and outcomes in large B-cell lymphoma @RShouval @KRejeski https://t.co/1D65shoYLQ

[Biagio Ricciuti, MD, PhD @BRicciutiMD]

Agree @PTarantinoMD, this trial has important (& very concerning) limitations. That said, the association is reproducible across >15 independent studies (some also biased, sure), and is supported by preclinical data in @CellCellPress (DOI: 10.1016/j.cell.2024.04.015) showing circadian regulation of tumor-infiltrating CD8⁺ T cells, with diurnal peaks in cytotoxicity and PD-1/ACT efficacy—implicating the endogenous clock as a biologically relevant modulator of immunotherapy response. Careful prospective validation is essential before any changes to clinical practice. @OncoAlert @FordePatrick @BalazsHalmosMD @StephenVLiu @DrJNaidoo @NarjustFlorezMD

[Krish Patel @KrishPatelMD]

@EricTopol Intriguing, Similar observation for use of CART cell therapy in lymphomas from @RShouval

https://t.co/nW1Tyq9FPz

[Danny Luan @DannyLuan6]

More rationale for a randomized, prospective clinical trial in CAR T-cell therapy, which would address much of the remaining confounders that we could not adjust for in our recent publication. https://t.co/S6mvk9KJQs

[Danny Luan @DannyLuan6]

Yet another example of early time-of-day immunotherapy leading to improved clinical outcomes, this time in NSCLC! https://t.co/AIqKNOICYi

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

New MSK research suggests circadian rhythms may influence how patients respond to CAR T cell therapy for large B cell #lymphoma. Patients treated before noon showed higher 1-year progression-free survival.

“The link between circadian rhythms and treatment effectiveness is a relatively new area of research,” says MSK's @RShouval. “By studying this connection, we hope to improve the way CAR T therapy is administered, so that more people can benefit from this potentially lifesaving therapy.” Learn more: https://t.co/9Yujv3NRsk

[Graham Collins @graham74GC]

Intriguing data from Luan et al. Time of CAR-T infusion may influence outcome.
• multicentre retrospect, 1052 pts
• rel / ref DLBCL
• med infn time 11.48am
• every hr later assoc with worse outcome
• 1y PFS 51% < 12pm, 35% > 12pm
#lymsm

https://t.co/D6j718GRqB

[Danny Luan @DannyLuan6]

Excited to share the online-first edition of our recent study looking at time of day and CAR-T outcomes in LBCL.

Across 7 large centers, we found a robust PFS benefit among early infusions. A multinational effort supervised by @RShouval and @KRejeski

https://t.co/IV4WkTA46X

[Danny Luan @DannyLuan6]

My cofellows at @WCMHemOncFellow bridging all 3 years! Can’t imagine a better group of colleagues for another trip to #ASH2025

[Danny Luan @DannyLuan6]

Happy to share that our paper on immune reconstitution following CAR-T was published in @BCD_AACR https://t.co/orzkwiDUzR
Thank you @RShouval and lab for the guidance and mentorship! #cart #immunology #lbcl

[Justin Kaner @JKanerMD]

Poster #2034

#ASH24

Patterns of Immune Reconstitution and Their Clinical Significance in Aggressive Lymphoma Treated with CAR-T Therapy

Presented by 3rd year @WCMDeptofMed @WeillCornell Resident @DannyLuan6 and newly matched class of 2028 @WCMHemOncFellow !!

[WCMHemOncFellow @WCMHemOncFellow]

We’re excited to announce our incoming 2025 @WeillCornell @nyphospital Hematology & Medical Oncology fellows! We can’t wait for them to officially join us on campus in July 2025!